PT Semen Indonesia (Persero) Tbk (PSGTF) Fair Value & Analysis
Basic Materials · US · Market cap $796M
Analysis
PT Semen Indonesia (Persero) Tbk (PSGTF) currently trades at $0.1200, while our model-based Fair Value estimate is $0.2200 — implying the stock looks roughly 83.3% undervalued today. We read business quality at 87/100 (high quality), in the Basic Materials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
About the company
PT Semen Indonesia (Persero) Tbk manufactures, packs, and distributes cement in Indonesia and internationally. It operates through Cement Production and Non-Cement Production segments. The company is also involved in limestone and clay mining; cement bag manufacturing; industrial real estate development and building rental; ready-mix concrete and aggregates quarry production; and mining, trading, transportation, and construction activities. In addition, it engages in the information system, investment, freight forwarding, stevedoring, sea transportation service, logistic management, and outsourcing businesses, as well as procures public goods and services. PT Semen Indonesia (Persero) Tbk was formerly known as PT Semen Gresik (Persero) Tbk and changed its name to PT Semen Indonesia (Persero) Tbk in January 2013. The company was founded in 1953 and is headquartered in Jakarta Selatan, Indonesia. PT Semen Indonesia (Persero) Tbk operates as a subsidiary of PT Danantara Asset Managemen…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.